

Aims

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the "classic" clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.

With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 13th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 13th AIBCC will award the 7th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists and nurses.

Programme

8.00	Registration
9.15	Introduction to the Conference Pier Franco Conte, Gabriel N. Hortobagyi
	SESSION I - LIFE STYLE AND BREAST CANCER Chairmen: Gabriel N. Hortobagyi, Stefania Migliuolo
9.30	Body Mass Index: role as risk factor and predictor of endocrine therapy efficacy Andrea De Censi
10.00	Hormone replacement therapy: the good and the bad Marco Gambacciani
10.30	Breast cancer and pregnancy Fedro Peccatori
11.00	Q&A
11.15	Coffee break
	SESSION II - HIGH RISK WOMEN AND PERSONALISED SCREENING Chairman: Andrea De Censi
11.45	Identification of high risk women: from family history to multigene panels Marco Montagna
12.15	Personalized screening (including women with dense breasts or breast implants/augmentation) Enrica Baldan
12.45	Q&A
13.00	Lunch

14.00 Multidisciplinary Tumor Board 1 – Management of women at high risk of breast cancer

Chairmen: Gabriel N. Hortobagyi, Luigi Pescarini

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Enrica Baldan, Maria Joao Cardoso, Andrea De Censi, Marco Gambacciani, Sibylle Loibl, Stefania Migliuolo, Marco Montagna, Stefania Montemezzi, Enrico Orvieto, Fedro Peccatori, Massimo Rugge

SESSION III - SURGERY & RADIOTHERAPY

Chairmen: Jacek Jassem, Elefterios Mamounas

- 15.00 Management of in situ carcinoma: state of art Maria Joao Cardoso
- 15.30 Sentinel node biopsy: when should be spared?
 Oreste Gentilini
- 15.50 Sentinel node biopsy: before or after NACT? Elefterios Mamounas
- 16.10 **Lipofilling: are preclinical data fully reassuring?** Francesco Bertolini
- 16.30 Lipofilling after breast cancer: the surgeon's point of view Vincenzo Vindigni
- 16.50 Radiation therapy: when more is better and when less is good Philip Poortmans
- 17.20 **Q&A**
- 17.30 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2017
- 18.00 Lecture of the Awardee
- 18.30 Cocktail
- 20.00 Adjourn

The Cocktail will take place at the Caffè Pedrocchi, Via VIII Febbraio 15 – Padova

Friday, September 22nd

	Chairmen: Aleix Prat, Massimo Rugge
9.00	Baseline assessment: new AJCC classification Gabriel N. Hortobagyi
9.30	HER2 testing guidelines for the clinicians: equivocal means yes or no? Giuseppe Viale
10.00	Genomic tests: clinical utility after TailoRx and Mindact Maria Vittoria Dieci
10.30	Liquid biopsy (ctDNA, CTC, miRNA): ready for clinical use? Leticia de Mattos-Arruda
11.00	Q&A
11.15	Coffee Break
	SESSION V - ACTIONABLE PATHWAYS IN BREAST CANCER SUBTYPES Chairmen: Pierfranco Conte, Sibylle Loibl
11.45	Luminal tumors and endocrine resistance Stephen Johnston
12.15	Targeting the immune system: TN and beyond Peter Schmid
12.45	HER2+ and trastuzumab resistance Aleix Prat
13.15	Q&A
13.30	Lunch

SESSION IV - PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY

14.30 Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (including CUP syndrome, breast cancer during pregnancy)

Chairman: Pierfranco Conte

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Maria Joao Cardoso, Hesham A. Gaballah Elghazaly, Gabriel N. Hortobagyi, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Elefterios Mamounas, Miguel Martin, Stefania Migliuolo, Fedro Peccatori, Philip Poortmans, Aleix Prat, Massimo Rugge, Giuseppe Viale

16.00 Coffee break

SESSION VI - ADJUVANT TREATMENTS

Chairmen: Gabriel N. Hortobagyi, Stephen Johnston

- 16.20 **HR+ disease: when more is better** Hope Rugo : when less is good Giuseppe Curigliano
- 17.00 **HER2+ disease: when more is better** Antonio Llombart -Cussac : **when less is good** Pier Franco Conte
- 17.40 **Triple Negative: when more is better** Valentina Guarneri : **when less is good** Miguel Martin
- 18.20 **Q&A**
- 18.30 Adjourn

Saturday, September 23rd

SESSION VII - ABC PATIENTS

Chairmen: Hesham A. Gaballah Elghazaly, Valentina Guarneri

9.00 New therapeutic algorithms
 HR+ ABC - Stephen Johnston
 HER2+ ABC - Sibylle Loibl
 TN ABC - Hope Rugo

- 10.30 **Q&A**
- 10.45 **Highlights from major meeting (ASCO, ESMO, SABCS, ST GALLEN)**Jassem Jacek
- 11.15 Coffee break
- 11.45 Multidisciplinary Tumor Board 3 Management of Advanced Breast Cancer

Chairmen: Pierfranco Conte, Miguel Martin

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Pier Franco Conte, Giuseppe Curigliano, Hesham A. Gaballah Elghazaly, Valentina Guarneri, Jacek Jassem, Gabriel N. Hortobagyi, Stephen Johnston, Sibylle Loibl, Stefania Migliuolo, Fedro A. Peccatori, Philip Poortmans, Aleix Prat, Hope Rugo

13.15 Adjourn and final evaluation questionnaire

Directors

Pier Franco Conte

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Gabriel N. Hortobagyi

Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA)

Scientific Committee

Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine University of Ainshams Cairo (EG)

Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

Sibylle Loibl

German Breast Group Department of Medicine and Research University of Frankfurt (D)

Miguel Martin

Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (S)

Stefania Migliuolo

Europa Donna Italia Milan (I)

Fedro Alessandro Peccatori

Department of Medical Oncology European Institute of Oncology (IEO) Milan (I)

Philip Poortmans

President of ESTRO; President-Elect of ECCO Department of Radiation Oncology Institut Curie Paris (F)

Aleix Prat

Institute of Oncology (VHIO) Vall d'Hebron - Institute of Oncology Barcellona (E)

Speakers & Chairmen

Enrica Baldan

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Francesco Bertolini

Department of Emato-Oncology European Institute of Oncology University of Milan (I)

Maria Joao Cardoso

Breast Unit Fondation Champalimaud Lisbon (P)

Giuseppe Curigliano

Department of Oncology European Institute of Oncology University of Milan (I)

Andrea De Censi

Medica and Preventive Oncology E.O. Galliera Hospital Genua (I)

Leticia De Mattos-Arruda

Institute of Oncology Vall d'Hebron (VHIO) Barcellona (S)

Maria Vittoria Dieci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Marco Gambacciani

Obstetrics & Gynecology Unit S. Chiara Hospital Pisa (I)

Oreste Gentilini

Breast Unit S. Raffaele Hospital Milan (I)

Antonio Llombart-Cussac

Medical Oncology Service University Hospital Arnau de Vilanova Valencia (S)

Eleuterios Mamounas

Comprehensive Breast Program MD Anderson Cancer Center Orlando (USA)

Marco Montagna

Hereditary Tumors Group Breast and Ovary Cancer Department of Oncological Molecular Diagnostic and Immunology Istituto Oncologico Veneto University of Padua (I)

Stefania Montemezzi

Department of Radiology University Hospital Verona (I)

Enrico Orvieto

General Pathology and Cythopatology Unit Department of Medicine-DIMED University of Padua (I)

Luigi Pescarini

Department of Radiology Diagnostic Breast Unit Istituto Oncologico Veneto IRCCS University of Padua (I)

Massimo Rugge

General Pathology & Cytopathology Unit Department of Medicine-DIMED University of Padua (I)

Hope Rugo

Breast Oncology Clinical Trials Program UCSF Carol Franc Buck Breast Care Center San Francisco (USA)

Peter Schmid

Centre for Experimental Cancer Medicine Bart Cancer Institute Queen Mary University London (UK)

Giuseppe Viale

Department of Pathology European Institute of Oncology University of Milan (I)

Vincenzo Vindigni

Unit of Plastic and Reconstructive Surgery University of Padua (I)

Awards & Fellowships

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2017

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. Prof. Conte and Prof. Hortobagyi will select the final winner which will be invited to present his/her study during the annual Conference.

CASE HISTORIES

Participants can send one or more case history to the scientific committee. The selected ones will be discussed during one of the three tumor boards (please see the program).

People sending the selected case histories will have to present them and will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement 200,00 \in for Italian participants and \in 300,00 for European participants).

Case histories should be sent within July 1st.

A confirmation will be sent by email within July 20th.

For further details (such as time limit, number of slides to prepare and so on) please do not hesitate to send an email to manganelli@accmed.org.

FELLOWSHIPS

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within July 1st.

The organizing secretariat will confirm the award of the fellowship within July 20th and it will proceed with the organization of logistics.

Under 35

Free admission is available for 3 people "under 35". Registration forms will be accepted on a first-come, first-served basis until spaces will be full. The Organization Secretariat will confirm the registration by email.





Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will request the MCE Accreditation.

The Meeting is addressed to physicians specialized in clinical pathology, general surgery, gynaecology and obstetrics, oncology, radiodiagnostics, radiotherapy. Biologists and nurses.

It will not be possible to give credits to physicians specialized in different fields.

The credit certification is subject to:

- attendance at least 90% of the Meeting
- the completion of the Meeting evaluation form
- the completion of the final questionnaire (at least 75% of correct answers).

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

Registration

The registration fee are:

- € **250,00** - € **150,00** for graduate students - € **150,00** for nurses They include the conference bag and all coffee breaks and lunches. They do not include Hotel accomodation, dinners and travel expenses.

To register, please send:

- registration form duly filled out (even when sponsored by a Pharmaceutical Company)
- privacy statement and consent to the use of personal data (as in the back of the form)
- payment

to Accademia Nazionale di Medicina - Galleria Ugo Bassi 2, 40121 Bologna (fax 0039 51 0569162 – e.mail: info.bologna@accmed.org), **within August 25th, 2017.**

Online registration is possible on the website **http://meettheprofessor.accmed.org.**

By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat.

Incomplete registration will NOT be admitted.

The registration will be confirmed by e-mail, please put your e-mail address on the registration form.

CANCELLATION

- if the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee.
- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

Meeting Venue

Palazzo del Bo Via VIII Febbraio, 2 Padua (I)

How to reach the meeting venue:

By Plane

Venezia Airport - Marco-Polo: 43 km (about 40 minutes by car) Treviso Airport- Canova: 63 km (about 50 minutes by car)

By Car:

The Highway exit is Padova Est, 5 Km from the Meeting Venue Palazzo Bo lies in a limited traffic area (ZTL) where cars are not allowed without a special permission. The nearest parking is Park Piazza Insurrezione, Piazza Insurrezione XXVIII Aprile '45, 10B and Parking in Piazza Rabin.

By Train:

Connections are provided by a bus service (Busitalia), running every half an hour to the Padova train Station, which is close to the city centre. From there you can reach Palazzo Bo on foot in about 15 minutes. There is a also a tram service - Sir 1 line - running every 10 minutes from the station to the vicinity of Palazzo Bo (Ponti Romani tram stop).

